Kymera Therapeutics (KYMR) Research & Development (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Research & Development data on file, last reported at $25.0 million in Q1 2026.

• On a quarterly basis, Research & Development fell 5.37% year-over-year to $25.0 million in Q1 2026; TTM through Mar 2026 was $308.1 million, a 145.09% increase from a year earlier, with the FY2025 full-year figure at $316.6 million, up 272.52% from the prior year.
• Research & Development for Q1 2026 stood at $25.0 million, down from $244.9 million in the prior quarter.
• Over the last five years, Research & Development for KYMR reached as high as $244.9 million in Q4 2025 and fell as low as -$41.4 million in Q4 2023.
• Historically, Research & Development has averaged $43.6 million across 5 years, with a median of $41.3 million in 2022.
• Across the five-year window, Research & Development plunged 196.01% in 2023 and soared 820.67% in 2025, its largest moves.
• Year by year, Research & Development stood at $43.1 million in 2022, then plunged by 196.01% to -$41.4 million in 2023, then surged by 164.24% to $26.6 million in 2024, then surged by 820.67% to $244.9 million in 2025, then tumbled by 89.81% to $25.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $25.0 million in Q1 2026, $244.9 million in Q4 2025, and $22.0 million in Q3 2025.